CNS Drugs

, Volume 14, Issue 5, pp 367–379

Extrapyramidal Symptoms Associated with Selective Serotonin Reuptake Inhibitors

Epidemiology, Mechanisms and Management
  • Félix Javier Jiménez-Jiménez
  • José Antonio Molina
Review Article

Abstract

In recent years there has been an increasing number of reports of the development or aggravation of parkinsonism and the development of other movement disorders (‘extrapyramidal symptoms’) associated with exposure to the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) fluoxetine, paroxetine, sertraline, fluvoxamine and citalopram. The exact prevalence of these complications is unknown since available information comes from literature reviews of case reports or data from the manufacturers or from movement disorders units and is therefore subject to reference bias. In addition, many of the patients had previously received or were concurrently being treated with other drugs, mainly antipsychotics. Reported movement disorders include parkinsonism, akathisia, tremor, dystonia, tardive dyskinesia, myoclonus, tics and chorea; parkinsonism and akathisia were the most frequent.

Pathophysiological mechanisms are not well established, but the most accepted hypotheses suggest a relationship with interactions between serotonergic and dopaminergic neurotransmitter systems. Anatomical, physiological and pharmacological relationships between these two systems are reviewed in this article.

The management of SSRI-induced movement disorders includes avoidance of SSRI use, dose reduction or discontinuation of the offending drug and the same measures that are used for treating antipsychotic-induced movement disorders.

References

  1. 1.
    Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507–33PubMedCrossRefGoogle Scholar
  2. 2.
    Rothschild AJ, Locke CA. Reexposure to fluoxetine alter serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52: 491–3PubMedGoogle Scholar
  3. 3.
    Lançon C, Bernard D, Bougeral T. Fluoxétine, akathisie et suicide. Encéphale 1997; 23: 218–23PubMedGoogle Scholar
  4. 4.
    Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449–54PubMedCrossRefGoogle Scholar
  5. 5.
    Caley CF. Extrapyramidal reactions and the selective serotoninreuptake inhibitors. Ann Pharmacother 1997; 31: 1481–9PubMedGoogle Scholar
  6. 6.
    Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32: 692–8PubMedCrossRefGoogle Scholar
  7. 7.
    Leo RJ. Movement disorders associated with the use of serotonin selective reuptake inhibitors. Ann Pharmacother 1998; 32: 712–4PubMedCrossRefGoogle Scholar
  8. 8.
    Watts MW, Tan EK, Jankovic J. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio 1999; 17: 196–201PubMedGoogle Scholar
  9. 9.
    Horga JF, Navarro M, Peiró V, et al. Trastornos extrapiramidales inducidos por fármacos. Rev Neurol 1995; 23: 961–3PubMedGoogle Scholar
  10. 10.
    Jiménez-Jiménez FJ, Ortí-Pareja M, Ayuso-Peralta L, et al. Drug-induced parkinsonism in a Movement disorders unit: a four-year survey. Parkinson Relat Disord 1996; 2: 145–9CrossRefGoogle Scholar
  11. 11.
    Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, et al. Parkinsonism exacerbated by paroxetine. Neurology 1994; 44: 2406PubMedCrossRefGoogle Scholar
  12. 12.
    Ortí-Pareja M, Jiménez-Jiménez FJ, Vázquez A, et al. Drug-induced tardive syndromes. Parkinson Relat Disord 1999; 5: 59–65CrossRefGoogle Scholar
  13. 13.
    Wetssman MW, Klerman GL. Sex difference and the epidemiology of depression. Arch Gen Psychiatry 1977; 34: 98–111CrossRefGoogle Scholar
  14. 14.
    Meltzer HY, Young M, Metz J, et al. Extrapyramidal side-effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45: 165–75PubMedCrossRefGoogle Scholar
  15. 15.
    Bouchard RH, Pourcher E, Vincent R. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989; 146: 1352–3Google Scholar
  16. 16.
    Brod TM. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989; 146: 1353Google Scholar
  17. 17.
    Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine [letter]. Am J Psychiatry 1989; 146: 399PubMedGoogle Scholar
  18. 18.
    Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry 1990; 51: 344–5PubMedGoogle Scholar
  19. 19.
    Gernaat HB, Van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine [letter]. Am J Psychiatry 1991; 141: 118–9Google Scholar
  20. 20.
    Wils V. Extrapyramidal symptoms in a patient treated with fluvoxamine [letter]. J Neural Neurosurg Psychiatry 1992; 55: 330–1CrossRefGoogle Scholar
  21. 21.
    Touw DJ, Gernaat HB, van der Woude J. Parkinsonism na toeroeging van fluoxetine aan behandeling met neuroleptica of carbamazepine [abstract]. Ned Tijdschr Geneeskd 1992; 136: 322–4Google Scholar
  22. 22.
    Daric C, Dollfus S, Mihout B, et al. Fluoxetine et symptomes extrapyramidaux. A propos de deux observations. Encephale 1993; 19: 61–2PubMedGoogle Scholar
  23. 23.
    Berk M. Paroxetine induced dystonia and parkinsonism in obsessive compulsive disorder. Hum Psychopharmacol 1993; 8: 444–5Google Scholar
  24. 24.
    Cano A, Roquer J. Parkinsonismo secundario al uso de sertralina. Med Clin (Barc) 1995; 105: 797–8Google Scholar
  25. 25.
    Malek-Ahmadi P, Allen SA. Paroxetine-molindone interaction [letter]. J Clin Psychiatry 1995; 56: 82–3PubMedGoogle Scholar
  26. 26.
    Leo R, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine. A case report. J Geriatr Psychiatry Neurol 1995; 8: 231–3Google Scholar
  27. 27.
    Singh RK, Gupta AK, Singh B. Acute organic brain syndrome after fluoxetine treatment. Am J Psychiatry 1995; 152: 295–6PubMedGoogle Scholar
  28. 28.
    Haenel T, Stockil HR, Truog P. Ein Fall von seltenen Nebenwirkungen gewiser Antidepressiva [abstract]. Nervenarzt 1995; 66: 70–2PubMedGoogle Scholar
  29. 29.
    Thomas P, Roche J, Maron M, et al. Severe extrapyramidal symptoms with fluvoxamine despite neuroleptic withdrawal. Eur Psychiatry 1996; 11: 273PubMedCrossRefGoogle Scholar
  30. 30.
    Rolling P, Jansen-Steur EN, de Burlet HM. Extrapiramidale stoornissen na sertralinegebruik; ervaringen met een nieuw selectief antidepressivum [abstract]. Ned Tijdschr Geneeskd 1996; 140: 1467–8Google Scholar
  31. 31.
    Schechter DS, Nunes EV. Reversible parkinsonism in a 90-year old man taking sertraline [letter]. J Clin Psychiatry 1997; 58: 275PubMedCrossRefGoogle Scholar
  32. 32.
    Kurlan R. Acute parkinsonism induced by the combination of a serotonin reuptake inhibitor and a neuroleptic in adults with Tourette’s syndrome. Mov Disord 1998; 13: 178–9PubMedCrossRefGoogle Scholar
  33. 33.
    Pina-Latorre MA, Zabala-López S. Parkinsonismo reversible secundario a la toma de sertralina. Neurología 1998; 13: 444–5PubMedGoogle Scholar
  34. 34.
    Di Rocco A, Brannan T, Prikhojan A, et al. Sertraline-induced parkinsonism. A case report and in-vivo study of the effect or sertraline on dopamine metabolism. J Neural Transm 1998; 105: 247–51PubMedGoogle Scholar
  35. 35.
    Jiménez-Jiménez FJ, García-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997; 16: 180–204PubMedCrossRefGoogle Scholar
  36. 36.
    Richard IH, Kurlan R, and the Parkinson Study Group. A survey of antidepressant drug use in Parkinson’s disease. Neurology 1997; 49: 1168–70PubMedCrossRefGoogle Scholar
  37. 37.
    Chouinard G, Sultan S. A case of Parkinson’s disease exacerbated by fluoxetine. Hum Psychopharmacol 1992; 7: 63–6CrossRefGoogle Scholar
  38. 38.
    Jansen Steur ENH. Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–3CrossRefGoogle Scholar
  39. 39.
    Gatto EM, Fernandez-Pardal M, Micheli F. Agravación del parkinsonismo por fluoxetina [letter]. Medicina (B Aires) 1994; 54: 182Google Scholar
  40. 40.
    Meco G, Bonifati V, Fabrizio E, et al. Worsening of parkinsonism with fluvoxamine — two cases. Hum Psychopharmacol 1994; 9: 439–41CrossRefGoogle Scholar
  41. 41.
    Linazasoro G. Worsening of Parkinson’s disease by citalopram. Parkinson Relat Disord 2000; 6: 111–3CrossRefGoogle Scholar
  42. 42.
    Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 1992; 53: 278–82PubMedGoogle Scholar
  43. 43.
    Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 1995; 10: 355–7PubMedCrossRefGoogle Scholar
  44. 44.
    Simons JA. Fluoxetine in Parkinson’s disease. Mov Disord 1996; 11: 581–2PubMedCrossRefGoogle Scholar
  45. 45.
    Durif F, Vidailhet M, Bonnet AM, et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995; 45: 1855–8PubMedCrossRefGoogle Scholar
  46. 46.
    Mathen D, Marsden CD, Bhatia KP. SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia. Mov Disord 1999; 14: 874–6PubMedCrossRefGoogle Scholar
  47. 47.
    Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1997; 12: 756–9PubMedCrossRefGoogle Scholar
  48. 48.
    Coulter DM, Pillans PI. Fluoxetine and extrapyramidal effects. Am J Psychiatry 1995; 152: 122–5PubMedGoogle Scholar
  49. 49.
    Ketai RF. Interaction between fluoxetine and neuroleptics [letter]. Am J Psychiatry 1993; 150: 836–7PubMedGoogle Scholar
  50. 50.
    Shihabuddin L, Rapport D. Sertraline and extrapyramidal side effects [letter]. Am J Psychiatry 1994; 151: 288PubMedGoogle Scholar
  51. 51.
    Lipinski Jr JF, Mallya G, Zimmermnan P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42PubMedGoogle Scholar
  52. 52.
    Maany I, Dhopesh V. Akathisia and fluoxetine. J Clin Psychiatry 1990; 51: 210–2PubMedGoogle Scholar
  53. 53.
    Friedman EH. Fluoxetine-induced akathisia in male OCD patients [letter]. J Clin Psychiatry 1990; 51: 212PubMedGoogle Scholar
  54. 54.
    Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychophar-macol 1991; 6: 51–8CrossRefGoogle Scholar
  55. 55.
    Fleischhacker WW. Propranolol for fluoxetine-induced akathisia [letter]. Biol Psychiatry 1991; 30: 531–2PubMedCrossRefGoogle Scholar
  56. 56.
    Fallon BA, Liebowitz MR. Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmacol 1991; 11: 147–8PubMedCrossRefGoogle Scholar
  57. 57.
    Hamilton MS, Opler LA. Akathisia, suicide, and fluoxetine. J Clin Psychiatry 1992; 53: 401–6PubMedGoogle Scholar
  58. 58.
    Wirshing WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia and suicidality: is there a causal connection [letter]? Arch Gen Psychiatry 1992; 49: 580–1PubMedCrossRefGoogle Scholar
  59. 59.
    Bertschy G, Vandel S. Fluoxetine-related indifference and akathisia. A case report. Therapie 1993; 48: 158–9Google Scholar
  60. 60.
    Marshall RD, Printz D, Cardenas D, et al. Adverse events in PTSD patients taking fluoxetine [letter]. Am J Psychiatry 1995; 152: 1238–9PubMedGoogle Scholar
  61. 61.
    Klee B, Kronig MH. Case report of probable sertraline-induced akathisia [letter]. Am J Psychiatry 1993; 150: 986–7PubMedGoogle Scholar
  62. 62.
    LaPorta LD. Sertraline-induced akathisia. J Clin Psychopharmacol 1993; 13: 219–20PubMedCrossRefGoogle Scholar
  63. 63.
    Lavin MR, Mendelewitz A, Block SH. Adverse reactions to high-dose fluoxetine [letter]. J Clin Psychopharmacol 1993; 54: 321Google Scholar
  64. 64.
    Settle Jr EC. Akathisia and sertraline [letter]. J Clin Psychiatry 1993; 54: 321PubMedGoogle Scholar
  65. 65.
    Opler LA. Sertraline and akathisia [letter]. Am J Psychiatry 1994; 151: 620–1PubMedGoogle Scholar
  66. 66.
    Altshuler LL, Pierre JM, Wirshing WC, et al. Sertraline and akathisia [letter]. J Clin Psychopharmacol 1994; 14: 278–9PubMedCrossRefGoogle Scholar
  67. 67.
    Phillips SD. A possible paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995; 152: 645–6PubMedGoogle Scholar
  68. 68.
    Adler LA, Angrist BM. Paroxetine and akathisia [letter]. Biol Psychiatry 1995; 37: 336–7PubMedCrossRefGoogle Scholar
  69. 69.
    Poyurovsky M, Meerovich I, Weizman A. Beneficial effect of low dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psychopharmacol 1995; 110: 111–4CrossRefGoogle Scholar
  70. 70.
    Baldassano CF, Truman CJ, Nierenberg A, et al. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996; 37: 122–4PubMedCrossRefGoogle Scholar
  71. 71.
    Lesaca TG. Fluvoxamine and akathisia. J Clin Psychopharmacol 1996; 16: 334CrossRefGoogle Scholar
  72. 72.
    Hoffman M, Vidoni F. SSRI-induzierte Akathisie. Psychiatr Prax 1996; 23: 143–4Google Scholar
  73. 73.
    Chong SA, Tan CH. Fluvoxamine and akathisia [letter]. J Clin Psychopharmacol 1996; 16: 334–5PubMedCrossRefGoogle Scholar
  74. 74.
    Olivera AA. Sertraline and akathisia: spontaneous resolution. Biol Psychiatry 1997; 41: 241–2PubMedCrossRefGoogle Scholar
  75. 75.
    Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12: 192–214PubMedCrossRefGoogle Scholar
  76. 76.
    Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine [letter]. Am J Psychiatry 1991; 148: 1263PubMedGoogle Scholar
  77. 77.
    Apseloff G, Wilner KD, von-Deutsch DA, et al. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers. J Clin Pharmacol 1992; 32: 643–6PubMedGoogle Scholar
  78. 78.
    Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994; 23: 1371–4PubMedCrossRefGoogle Scholar
  79. 79.
    Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal [letter]. Am J Psychiatry 1995; 152: 1234–5Google Scholar
  80. 80.
    Recoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine [letter]. J Clin Psychiatry 1990; 51: 487Google Scholar
  81. 81.
    Black B, Uhde TW. Acute dystonia and fluoxetine [letter]. J Clin Psychiatry 1992; 53: 327PubMedGoogle Scholar
  82. 82.
    Río J, Molins A, Viguera ML, et al. Distonía aguda por fluoxetina [letter]. Med Clín (Barc) 1992; 99: 46–7Google Scholar
  83. 83.
    George MS, Trimble MR. Dystonic reaction associated with fluvoxamine [letter]. J Clin Psychopharmacol 1993; 1: 220–1CrossRefGoogle Scholar
  84. 84.
    Dave M. Fluoxetine-associated dystonia [letter]. Am J Psychiatry 1994; 151: 149PubMedGoogle Scholar
  85. 85.
    Chong SA. Fluvoxamine and mandibular dystonia [letter]. Can J Psychiatry 1995; 40: 430–1PubMedGoogle Scholar
  86. 86.
    Murray V, Laryngeal dystonia. Br J Psychiatry 1995; 167: 698–9PubMedCrossRefGoogle Scholar
  87. 87.
    Rone LA, Ferrando SJ. Serotonin reuptake inhibitor-related extrapyramidal side effects in two patients with cerebral palsy. Psychosomatics 1996; 37: 165–6PubMedCrossRefGoogle Scholar
  88. 88.
    Marques C, Figeueira I, Nardi AE, et al. Acute dystonic reaction with fluoxetine: case report [abstract]. J Bras Psiquiatr 1996; 45: 51–4Google Scholar
  89. 89.
    Lewis CF, DeQuardo JR, Tandon R. Dystonia associated with trazodone and sertraline [letter]. J Clin Psychopharmacol 1997; 17: 64–5PubMedCrossRefGoogle Scholar
  90. 90.
    Poyurovsky M, Schneidman M, Weizman A. Successful treatment of fluoxetine-induced dystonia with low-dose mianserin. MovDisord 1997; 12: 1102–5CrossRefGoogle Scholar
  91. 91.
    Lauterbach EC, Meyer JM, Simpson GM. Clinical manifestation of dystonia and dyskinesia after SSRI administration. J Clin Psychiatry 1997; 58: 403–4PubMedCrossRefGoogle Scholar
  92. 92.
    Palop V, Jiménez MJ, Catalan C, et al. Acute dystonia associated with fluvoxamine-metoclopramide. Ann Pharmacother 1999; 33: 382–3PubMedCrossRefGoogle Scholar
  93. 93.
    Chong Y, Harris R, Kim WJ. Dystonia as a side effect of non-neuroleptics [letter]. J Am Acad Child Adolesc Psychiatry 1999; 38: 793–5PubMedCrossRefGoogle Scholar
  94. 94.
    Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychatr Serv 1996; 47: 991–3Google Scholar
  95. 95.
    Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine [letter]. Am J Psychiatry 1991; 148: 1403PubMedGoogle Scholar
  96. 96.
    Fitzgerald K, Healy D. Dystonias and dyskinesias of the jaw associated with the use of SSRIs. Hum Psychopharmacol 1995; 10: 215–9CrossRefGoogle Scholar
  97. 97.
    Oslin DW, Duffy K. Dyskinesia associated with fluvoxamine. J Clin Psychopharmacol 1993; 13: 365–6CrossRefGoogle Scholar
  98. 98.
    Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993; 54: 432–4PubMedGoogle Scholar
  99. 99.
    Rommanelli F, Adler DA, Bungay KM. Possible paroxetine-induced bruxism. Ann Pharmacother 1996; 30: 1246–8Google Scholar
  100. 100.
    Christensen RC, Byerly MJ. Mandibular dystonia associated with the combination of sertraline and metoclopramide [letter]. J Clin Psychiatry 1996; 57: 596PubMedCrossRefGoogle Scholar
  101. 101.
    Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine [letter]. Am J Psychiatry 1991; 148: 683PubMedGoogle Scholar
  102. 102.
    Clarke CE, Bamford JM, House A. Dyskinesia in Creutzfeldt-Jakob disease precipitated by antidepressant therapy. Mov Disord 1992; 7: 86–7PubMedCrossRefGoogle Scholar
  103. 103.
    Fishbain DA, Domínguez M, Goldberg M, et al. Dyskinesia associated with fluoxetine use. Neuropsychiatry Neuropsychol Behav Neurol 1992; 5: 97–100Google Scholar
  104. 104.
    Arya DK, Szabadi E. Dyskinesia associated with fluvoxamine. J Clin Psychopharmacol 1993; 13: 365–6PubMedCrossRefGoogle Scholar
  105. 105.
    Mander A, McCausland M, Workman B, et al. Fluoxetine induced dyskinesia. Aust NZ J Psychiatry 1994; 28: 328–30CrossRefGoogle Scholar
  106. 106.
    al-Adwani A. Brain damage and tardive dyskinesia [letter]. Br J Psychiatry 1995; 167: 410–1PubMedCrossRefGoogle Scholar
  107. 107.
    Sandler NH. Tardive dyskinesia associated with fluoxetine [letter]. J Clin Psychiatry 1996; 57: 91PubMedGoogle Scholar
  108. 108.
    Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord 1996; 11: 324–6PubMedCrossRefGoogle Scholar
  109. 109.
    Botsaris SD, Sypek JM. Paroxetine and tardive dyskinesia [letter]. J Clin Psychopharmacol 1996; 16: 258–9PubMedCrossRefGoogle Scholar
  110. 110.
    Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–5PubMedGoogle Scholar
  111. 111.
    Jahr JS, Pisto JD, Gitlin MC, et al. The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg 1994; 79: 189–91PubMedCrossRefGoogle Scholar
  112. 112.
    Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick’s disease. Mov Disord 1994; 9: 343–6PubMedCrossRefGoogle Scholar
  113. 113.
    Bronner IM, Vanneste JAL. Complex movement disorder associated with fluvoxamine. Mov Disord 1998; 13: 848–50PubMedCrossRefGoogle Scholar
  114. 114.
    Ghika-Schmid F, Ghika J, Vuadens P, et al. Acute reversible myoclonic encephalopathy associated with fluoxetine therapy. Mov Disord 1997; 12: 622PubMedCrossRefGoogle Scholar
  115. 115.
    Cunningham M, Cunningham K, Kydiard RB. Eye tics and subjective hearing impairment during fluoxetine therapy [letter]. Am J Psychiatry 1990; 147: 947–8PubMedGoogle Scholar
  116. 116.
    Eisenhauer G, Jermain DM. Fluoxetine and tics in an adolescent. Ann Pharmacother 1993; 27: 725–6PubMedGoogle Scholar
  117. 117.
    Hauser RA, Zesiewicz TA. Sertraline-induced exacerbation of tics in Tourette’s syndrome. Mov Disord 1995; 10: 682–4PubMedCrossRefGoogle Scholar
  118. 118.
    Silvestri R, Raffaele M, De Domenico P, et al. Serotoninergic agents in the treatment of Gilles de la Tourette’ s syndrome. Acta Neurol Napoli 1994; 16: 58–63PubMedGoogle Scholar
  119. 119.
    Scahill L, Riddle MA, King RA, et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997; 7: 75–85PubMedCrossRefGoogle Scholar
  120. 120.
    Marchioni E,PeruccaE, SoragnaD, et al. Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology 1996; 46: 853PubMedGoogle Scholar
  121. 121.
    Arya DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994; 165: 728–33PubMedCrossRefGoogle Scholar
  122. 122.
    Cooper JR, Bloom FE, Roth RH. Dopamine. In: Cooper JR, Bloom FE, Roth RH, editors. The biochemical basis of neuropharmacology. 6th edition. New York-Oxford: Oxford University Press, 1991: 285–337Google Scholar
  123. 123.
    Cooper JR, Bloom FE, Roth RH. Serotonin (5-hydroxytryptamine) and histamine. In: Cooper JR, Bloom FE, Roth RH, editors. The biochemical basis of neuropharmacology. 6th edition. New York-Oxford: Oxford University Press, 1991: 338–80Google Scholar
  124. 124.
    Luquin MR, Jiménez-Jiménez FJ. Anatomía funcional de los ganglios basales. In: Jiménez-Jiménez FJ, Luquin MR, Molina JA, editors. Tratado de los trastornos del movimiento. Madrid: IM & C, 1998: 19–41Google Scholar
  125. 125.
    Miller JJ, Richardson TL, Fibiger HC, et al. Anatomical and electrophysiological identification of a projection from the mesencephalonic raphe to the caudate putamen in the rat. Brain Res 1975; 97: 133–8PubMedCrossRefGoogle Scholar
  126. 126.
    Bobillier P, Seguin S, Petitjean F, et al. The raphe nuclei of the cat brain stem: a topographical atlas of their afferent projections as revealed by autoradiography. Brain Res 1976; 113: 449–86PubMedCrossRefGoogle Scholar
  127. 127.
    Jacobs BL, Foote SL, Bloom FE. Differential projections of the neurones within the dorsal raphe nucleus of the rat: a horseradish peroxidase (HRP) study. Brain Res 1978; 147: 149–53PubMedCrossRefGoogle Scholar
  128. 128.
    Nicolaou N, García-Muñoz M, Arbuthnott G, et al. Interaction between serotonergic and dopaminergic systems in rats demonstrated by small unilateral lesions of the raphe nuclei. Eur J Pharmacol 1979; 57: 295–305PubMedCrossRefGoogle Scholar
  129. 129.
    Van der Kooy D, Hattori T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labelling study in rat. Brain Res 1980; 186: 1–7PubMedCrossRefGoogle Scholar
  130. 130.
    Herve D, Pickel VM, Hoh TH, et al. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 1987; 435: 71–83PubMedCrossRefGoogle Scholar
  131. 131.
    Phelix CF, Broderick PA. Light microscopic immunocytochemical evidence of converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. Brain Res Bull 1995; 37: 37–40PubMedCrossRefGoogle Scholar
  132. 132.
    Marsden CD, Gulberg HC. The role of monoamines in rotation induced or potentiated by amphetamine after nigral, raphe and mesencephalic reticular lesions in the rat brain. Neuropharmacology 1973;12: 195–211PubMedCrossRefGoogle Scholar
  133. 133.
    Bourgoin S, Enjalbert A, Adrien J, et al. Midbrain raphe lesions in the newborn rat: II. Biochemical alteration in serotoninergic innervation. Brain Res 1977;127: 111–26Google Scholar
  134. 134.
    Dray A, Davie J, Oakley NR, et al. The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res 1978; 151: 431–42PubMedCrossRefGoogle Scholar
  135. 135.
    Bolte-Taylor J, Cunningham MC, Benes FM. Neonatal raphe lesions increase dopamine fibers in prefrontal cortex of adult rats. Neuroreport 1998; 9: 1811–5PubMedCrossRefGoogle Scholar
  136. 136.
    Ennis E, Kemp JP, Cox B. Characterisation of inhibitors 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem 1981; 36: 1515–20PubMedCrossRefGoogle Scholar
  137. 137.
    Hetey L, Kudrin VS, Shemanow AY, et al. Presynaptic dopamine and serotonin receptors modulation of tyrosine-hydroxylase activity in synaptosomes of nucleus accumbens of rats. Eur J Pharmacol 1985; 113: 1–10PubMedCrossRefGoogle Scholar
  138. 138.
    Hetey L, Drescher K. Influence of antipsychotics on presynaptic receptors modulating the release of dopamine in synaptosomes of the nucleus accumbens of rats. Neuropharmacology 1986; 25: 1103–9PubMedCrossRefGoogle Scholar
  139. 139.
    Bleich A, Brown S, Kahn R, et al. The role of serotonin in schizophrenia. Schizophr Bull 1988; 14: 297–315PubMedCrossRefGoogle Scholar
  140. 140.
    Baldessarini RJ, Marsh E. Fluoxetine and side-effects. Arch Gen Psychiatry 1990; 47: 191–2PubMedCrossRefGoogle Scholar
  141. 141.
    Iyer RN, Bradberry CW. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 1996; 277: 40–7PubMedGoogle Scholar
  142. 142.
    Matsumoto M, Togashi H, Mori K, et al. Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur J Pharmacol 1999; 383: 39–48PubMedCrossRefGoogle Scholar
  143. 143.
    Penek EA. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse 1996; 24: 12–8CrossRefGoogle Scholar
  144. 144.
    Davies J, Tongroach P. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 1978; 1978; 51: 91–100PubMedCrossRefGoogle Scholar
  145. 145.
    Dray A, Gonye T, Oakley NR, et al. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res 1976; 113: 45–57PubMedCrossRefGoogle Scholar
  146. 146.
    Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 1994; 271: 83–90PubMedGoogle Scholar
  147. 147.
    Di Mascio M, Di Giovanni G, Di Matteo, et al. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 1998; 46: 547–54PubMedCrossRefGoogle Scholar
  148. 148.
    Faherty CJ, Earley B, Leonard BE. Behavioural effects of selective serotonin reuptake inhibitors following direct microinjection into the left red nucleus of the rat. J Psychopharmacol 1997; 11: 53–8PubMedCrossRefGoogle Scholar
  149. 149.
    Faherty CJ, Harkin AJ, Leonard BE. The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment. Eur J Pharmacol 1998; 346: 15–21PubMedCrossRefGoogle Scholar
  150. 150.
    Teicher MH, Klein DA, Andersen SL, et al. Development of an animal model of fluoxetine akathisia. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1305–19PubMedCrossRefGoogle Scholar
  151. 151.
    Sills TL, Greenshaw AJ, Baker GB, et al. Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: possible pharmacokinetic interaction. Psychopharmacology Berl 1999; 141: 421–7PubMedCrossRefGoogle Scholar
  152. 152.
    Korsgaard S, Gerlach J, Christenson E. Behavioural aspects of serotonin-dopamine interaction in monkey. Eur J Pharmacol 1985; 118: 245–52PubMedCrossRefGoogle Scholar
  153. 153.
    Downs DA, Fortune DH, Naylor RJ, et al. Buspirone effects in a primate model of extrapyramidal dysfunction [abstract]. Soc Neurosci Abstr 1985; 11: 426Google Scholar
  154. 154.
    Ishikane T. Effects of serotonergic drugs on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum [abstract]. Hokkaido Igaku Zasshi 1998; 73: 441–9PubMedGoogle Scholar
  155. 155.
    Milson JA, Pycock CJ. Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice. Br J Pharmacol 1976; 56: 77–85PubMedCrossRefGoogle Scholar
  156. 156.
    Jenner P, Sheehy M, Marsden CD. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson’s disease. Br J Clin Pharmacol 1983; 15 (Suppl.): 2779–898CrossRefGoogle Scholar
  157. 157.
    Cheshire RM, Cheng JT, Teitelbaum P. Antiserotonergic drugs reinstate galloping forward locomotion produced by pontine tegmentum damage in rats. In: Ho BT, Schoolar JC, Usdin E, editors. Serotonin in biological psychiatry. New York: Raven Press, 1982: 315–7Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Félix Javier Jiménez-Jiménez
    • 1
  • José Antonio Molina
    • 2
  1. 1.Department of Medicine-Neurology, Hospital ‘Príncipe de Asturias’Universidad de Alcalá, Alcalá de Henares (Madrid)MadridSpain
  2. 2.Service of NeurologyHospital Universitario ‘Doce de Octubre’MadridSpain
  3. 3.MadridSpain

Personalised recommendations